2096.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 10:08):

Stats
Dagens volum	6.34M
Gjennomsnittsvolum	5.06M
Markedsverdi	13.83B
EPS	HKD0 ( 2024-03-28 )
Neste inntjeningsdato	( HKD0 ) 2024-06-14
Last Dividend	HKD0.176 ( 2023-06-19 )
Next Dividend	HKD0 ( N/A )
P/E	18.28
ATR14	HKD0.00900 (0.17%)

Volum Korrelasjon

Lang: -0.14 (neutral)

Kort: 0.00 (neutral)

Signal:(57.063) Neutral

Simcere Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Simcere Pharmaceutical Korrelasjon - Valuta/Råvare

0.45
( neutral )

0.62
( weak )

0.00
( neutral )

-0.35
( neutral )

Simcere Pharmaceutical Økonomi

Annual	2023
Omsetning:	HKD6.61B
Bruttogevinst:	HKD4.98B (75.43 %)
EPS:	HKD0.270

FY	2023
Omsetning:	HKD6.61B
Bruttogevinst:	HKD4.98B (75.43 %)
EPS:	HKD0.270

FY	2023
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD0

FY	2022
Omsetning:	HKD6.32B
Bruttogevinst:	HKD5.00B (79.08 %)
EPS:	HKD0.400

Financial Reports:

No articles found.

Simcere Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.176 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Simcere Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.07 - good (70.71%) | Divividend Growth Potential Score: 1.023 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.180	2021-06-29
Last Dividend	HKD0.176	2023-06-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD0.532	--
Avg. Dividend % Per Year	0.00%	--
Score	1.74	--
Div. Sustainability Score	7.07
Div.Growth Potential Score	1.023
Div. Directional Score	4.05	--

Next Divdend (Est)
(2025-03-31)

HKD0.176 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.74

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
0217.HK	Ex Dividend Junior	2023-07-05	Sporadic	0.00%
3833.HK	Ex Dividend Junior	2023-06-02	Sporadic	0.00%
1713.HK	Ex Dividend Junior	2023-06-21	Annually	0.00%
0746.HK	Ex Dividend Knight	2023-08-11	Semi-Annually	0.00%
2314.HK	Ex Dividend Junior	2023-08-11	Semi-Annually	0.00%
1283.HK	Ex Dividend Junior	2023-09-22	Semi-Annually	0.00%
0341.HK	Ex Dividend Junior	2023-09-12	Annually	0.00%
6083.HK	Ex Dividend Knight	2023-06-12	Semi-Annually	0.00%
1843.HK	Ex Dividend Knight	2023-09-05	Annually	0.00%
0868.HK	Ex Dividend Knight	2023-08-11	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.108	1.500	7.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0659	1.200	7.80	9.37	[0 - 0.3]
returnOnEquityTTM	0.0878	1.500	-0.135	-0.203	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.10	0.800	4.50	3.60	[1 - 3]
quickRatioTTM	1.736	0.800	4.49	3.59	[0.8 - 2.5]
cashRatioTTM	0.747	1.500	6.96	10.00	[0.2 - 2]
debtRatioTTM	0.124	-1.500	7.93	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.0316	2.00	-0.0105	-0.0210	[0 - 30]
freeCashFlowPerShareTTM	-0.0316	2.00	-0.0158	-0.0316	[0 - 20]
debtEquityRatioTTM	0.187	-1.500	9.25	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.754	1.000	0.762	0.762	[0.2 - 0.8]
operatingProfitMarginTTM	0.111	1.000	9.78	9.78	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.0608	1.000	-1.449	-1.449	[0.2 - 2]
assetTurnoverTTM	0.609	0.800	9.27	7.42	[0.5 - 2]
Total Score				7.07

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.82	1.000	8.30	0	[1 - 100]
returnOnEquityTTM	0.0878	2.50	-0.0869	-0.203	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0316	2.00	-0.0105	-0.0316	[0 - 30]
dividendYielPercentageTTM	3.58	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0316	2.00	-0.0105	-0.0210	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0124	1.000	-2.81	0	[0.1 - 0.5]
Total Score				1.023

Simcere Pharmaceutical

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.